{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-25-000159","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.144965+00:00","generated_at":"2026-05-16T20:43:41.558148+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pfizer completes $7B acquisition of Metsera, including contingent milestones up to $20.65/sh","bullets":["Enterprise value ~$7.0B; each Metsera share converted into $65.60 cash at closing.","Plus up to $20.65/sh in contingent value rights tied to three FDA/clinical milestones.","Milestones: Phase 3 start for MET-097i+MET-233i combo ($4.60/sh), FDA nod for monthly MET-097i ($6.40/sh), FDA nod for combo ($9.65/sh).","Acquisition aimed at bolstering Pfizer's obesity pipeline with GLP-1 receptor antagonist + amylin analog."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-25-000159","json":"https://secwatch.observer/filing/0000078003-25-000159.json","markdown":"https://secwatch.observer/filing/0000078003-25-000159.md","text":"https://secwatch.observer/filing/0000078003-25-000159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/0000078003-25-000159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/pfe-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:43:41.558148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}